Related Experiment Video

Updated: May 11, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

PCSK9 inhibitors

Michel Farnier1

  • 1Department of Lipidology, Point Medical, Dijon, France. michelfarnier@nerim.net

Current Opinion in Lipidology
|May 9, 2013
PubMed
Abstract

Insights

Monoclonal antibodies targeting PCSK9 effectively lower LDL cholesterol by up to 70% in early trials. These PCSK9 inhibitors show promise for managing hypercholesterolemia, with larger studies underway.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biotechnology

Background:

  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating LDL cholesterol levels.
  • Inhibition of PCSK9 offers a novel therapeutic strategy for hypercholesterolemia.

Purpose of the Study:

  • To review therapeutic strategies for inhibiting PCSK9.
  • To summarize Phase I and II trial results of monoclonal antibodies targeting PCSK9.

Main Methods:

  • Review of preclinical and clinical trial data for PCSK9 inhibitors.
  • Focus on monoclonal antibodies (SAR236553/REGN727 and AMG145) targeting PCSK9-LDL receptor interaction.
  • Analysis of data from Phase II trials in hypercholesterolemic patients.

Main Results:

  • Monoclonal antibodies targeting PCSK9 are well-tolerated and effective in reducing atherogenic lipoproteins.
  • Significant reductions in LDL cholesterol (up to 70%) observed with PCSK9 inhibition.
  • Efficacy demonstrated in various patient groups, including those with familial hypercholesterolemia and statin intolerance.

Conclusions:

  • Short-term efficacy, safety, and tolerability of PCSK9 monoclonal antibodies are established in Phase II trials.
  • PCSK9 inhibitors are advancing to Phase III studies to assess long-term safety and clinical outcomes.
  • This approach represents a highly promising therapeutic strategy for managing cholesterol levels.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...